en-TEK-aveer
REMS
Contraindicated in:
Use Cautiously in:
Patients coinfected with HIV (unless receiving highly active antiretroviral therapy; at ↑ risk for resistance)
;Drug-drug:
Renal Impairment
Absorption: Well absorbed following oral administration.
Distribution: Extensive tissue distribution.
Half-Life: Plasma: 128–149 hr; intracellular: 15 hr.
Do not stop taking without consulting health care provider. Discontinuing therapy may lead to severe exacerbations.
Advise patient to notify health care provider promptly if signs of lactic acidosis (weakness or tiredness; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in arms or legs; dizziness; fast or irregular heartbeat) or hepatotoxicity (jaundice, dark urine, light-colored bowel movements, anorexia, nausea, lower stomach pain) occur.
NDC Code